MGTX trades 94.6% below Wall Street's consensus target of $21.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MGTX achieves its forward estimates and maintains a stable P/E multiple of 36.0x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, MeiraGTx Holdings plc (MGTX) has a Wall Street consensus price target of $21.00, based on estimates from 7 covering analysts. With the stock currently trading at $10.79, this represents a potential upside of +94.6%. The company has a market capitalization of $999M.
Analyst price targets range from a low of $16.00 to a high of $26.00, representing a 48% spread in expectations. The median target of $21.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MGTX trades at a trailing P/E of -7.6x and forward P/E of 36.0x. Analysts expect EPS to grow -64.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ADVMAdverum Biotechnologies, Inc. | $96M | $4.36 | — | — | — | — | — |
 OCGNOcugen, Inc. | $346M | $1.02 | $5.00 | +390.2% | Buy | — | 6 |
 EDITEditas Medicine, Inc. | $402M | $2.62 | $4.50 | +71.8% | Buy | — | 26 |
 CRSPCRISPR Therapeutics AG | $5.3B | $55.43 | $67.83 | +22.4% | Buy | — | 38 |
 NTLAIntellia Therapeutics, Inc. | $1.4B | $12.26 | $23.00 | +87.6% | Buy | — | 39 |
 BEAMBeam Therapeutics Inc. | $2.5B | $24.50 | $59.50 | +142.9% | Buy | — | 27 |
 SGMOSangamo Therapeutics, Inc. | $31M | $0.07 | $7.25 | +9697.3% | Hold | — | 14 |
 ARWRArrowhead Pharmaceuticals, Inc. | $9.0B | $64.19 | $100.63 | +56.8% | Buy | — | 22 |
 IONSIonis Pharmaceuticals, Inc. | $7.2B | $43.54 | $84.08 | +93.1% | Buy | — | 33 |
 ALNYAlnylam Pharmaceuticals, Inc. | $29.3B | $219.72 | $347.33 | +58.1% | Buy | 33.0x | 52 |
Quick answers to the most common questions about buying MGTX stock.
The consensus Wall Street price target for MGTX is $21, representing 94.6% upside from the current price of $10.79. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MGTX has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $21 implies 94.6% upside from current levels.
At a forward P/E of 35.9667x, MGTX trades at a premium valuation. The consensus price target of $21 (94.6% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $26 for MGTX, while the most conservative target is $16. The consensus of $21 represents the median expectation. These targets typically reflect 12-month expectations.
MGTX is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MGTX stock forecast based on 7 Wall Street analysts shows a consensus price target of $21, with estimates ranging from $16 (bear case) to $26 (bull case). The median consensus rating is "Buy".
MGTX trades at a forward P/E ratio of 36.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on MGTX, with a "Buy" consensus rating and $21 price target (94.6% upside). 7 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MGTX analyst price targets range from $16 to $26, a 48% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.